Sandoz, a Novartis division, and Biocon have entered a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.   Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and ea...